UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Apr

    20

    UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

    Read More Share:linkedin| twitter| email| facebook

    Jan

    06

    UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

    Read More Share:linkedin| twitter| email| facebook

    Nov

    14

    UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

    Read More Share:linkedin| twitter| email| facebook

    Sep

    22

    UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

    Read More Share:linkedin| twitter| email| facebook

    Jun

    01

    Life with MG & What I Wish For Everyone Who is Diagnosed

    Read More Share:linkedin| twitter| email| facebook

    May

    27

    My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

    Read More Share:linkedin| twitter| email| facebook

    May

    10

    UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Read More Share:linkedin| twitter| email| facebook

    Feb

    04

    UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

    Read More Share:linkedin| twitter| email| facebook

    Dec

    10

    UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)